IP Library Granted Patent US 9,139,813
Granted Patent B2
US 9,139,813 · App. 13/863,308 · Granted Sep 22, 2015

Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells

Inventor: Robert J. Hariri (Bernardsville, NJ)
Assignee: Anthrogenesis Corporation
C12N5/0605A61L27/3834A61M1/02C12N5/0068A61K35/12A61M2202/0462A61M2210/1458A61M2210/1466C12N2509/00C12N2533/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,139,813
App. No.
13/863,308
Granted
Sep 22, 2015
Kind
B2
Abstract

A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.

Claims (11)

1. A method of treating an individual in need of repair of traumatic injury of the skin comprising administering to the individual isolated placental stem cells, wherein said isolated placental stem cells have been seeded onto a decellularized or synthetic tissue matrix, wherein said placental stem cells are obtained from a mammalian placenta that has been drained of cord blood, and wherein said placental stem cells

(a) express antigens recognized by SH2, SH3 and SH4 antibodies;

(b) do not express MHC Class 2 antigens;

(c) are CD34 − , SSEA3 − , SSEA4 − , and OCT-4 + ;

(d) are SSEA3 − , SSEA4 − , OCT-4 + and ABC-p + ; or

(e) are CD10 + , CD29 + , CD34 − , CD44 + , CD45 − , CD54 + , CD90 + , SH2 + , SH3 + , SH4 + , SSEA3 − , SSEA4 − , OCT-4 + and ABC-p + .

2. The method of claim 1 , wherein said placental stem cells express antigens recognized by SH2, SH3 and SH4 antibodies.

3. The method of claim 1 , wherein said placental stem cells do not express MHC Class 2 antigens.

4. The method of claim 1 , wherein said placental stem cells are CD34 − , SSEA3 − , SSEA4 − , and OCT-4 + .

5. The method of claim 1 , wherein said placental stem cells are SSEA3 − , SSEA4 − , OCT-4 + and ABC-p + .

6. The method of claim 1 , wherein said placental stem cells are CD10 + , CD29 + , CD34 − , CD44 + , CD45 − , CD54 + , CD90 + , SH2 + , SH3 + , SH4 + , SSEA3 − , SSEA4 − , OCT-4 + , and ABC-p + .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2017
From: CLARITY ACQUISITION II LLC
To: CELULARITY, INC.
Reel/Frame 044780/0261 →
MERGER Recorded Nov 8, 2017
From: ANTHROGENESIS CORPORATION
To: CLARITY ACQUISITION II LLC
Reel/Frame 044413/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2014
From: HARIRI, ROBERT J.
To: ANTHROGENESIS CORPORATION
Reel/Frame 033655/0793 →
Continuity (5)
Division 12823063 · Jun 24, 2010
Division 11980012 · Oct 29, 2007
Continuation 10074976 · Feb 13, 2002
Provisional Application 60268560 · Feb 14, 2001
Related Publication 20130230497A1 · Sep 5, 2013